Women's and children's Hospital
Welcome,         Profile    Billing    Logout  
 23 Trials 
21 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Stork, Linda C
PNOC017, NCT03749187: BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

Recruiting
1
78
US
PARP Inhibitor BGB-290, BGB-290, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac
University of California, San Francisco, BeiGene USA, Inc.
Glioblastoma, IDH1 Gene Mutation, IDH2 Gene Mutation, Low Grade Glioma, Malignant Glioma, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma, WHO Grade II Glioma, WHO Grade III Glioma
06/26
07/29
Marshall, Helen S
NCT05116241: Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children

Completed
2
367
Europe, RoW
BPZE1 pertussis vaccine and placebo, BPZE1 pertussis vaccine and Boostrix, Placebo and Boostrix
ILiAD Biotechnologies
Bordetella Pertussis, Whooping Cough
05/24
05/24
OPTIWIN, NCT03457194: Optimising Protection for Pregnant Women and Infants With Maternal Vaccination

Active, not recruiting
N/A
73
RoW
Quadrivalent Influenza Vaccine, FluQuadri, DTP Vaccine (Multiple Actives), Adacel
Women's and Children's Hospital, Australia, Sanofi Pasteur, a Sanofi Company
Obesity
09/23
03/24
Bratkovic, go
NCT05099640 / 2021-000474-29: A Study of PTC923 in Participants With Phenylketonuria

Completed
3
157
Europe, Canada, US, RoW
PTC923, Placebo
PTC Therapeutics
Phenylketonuria
04/23
05/23
NCT05166161 / 2021-000497-28: A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria

Recruiting
3
200
Europe, Canada, Japan, US, RoW
PTC923, Sepiapterin
PTC Therapeutics
Phenylketonuria
04/26
04/26
COMPASS, NCT05371613 / 2021-005200-35: A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) Vs Idursulfase in Pediatric and Young Adult Participants with Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

Recruiting
2/3
54
Europe, Canada, US, RoW
tividenofusp alfa, idursulfase
Denali Therapeutics Inc.
Mucopolysaccharidosis II
12/25
12/25
NCT05549219 / 2022-000565-40: 24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants with PMM2-CDG

Recruiting
2
44
Europe, US
GLM101
Glycomine, Inc., Glycomine, Inc
Pmm2-CDG, Phosphomannomutase 2 Deficiency
11/25
11/25
Kirby, Maria L
NCT02840409 / 2017-001982-26: Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)

Active, not recruiting
2
109
Canada, US, RoW
Vinblastine, Bevacizumab, Avastin
The Hospital for Sick Children, Hoffmann-La Roche
Low Grade Glioma
07/24
08/26
Bailey, Laurie
COMPASS, NCT05371613 / 2021-005200-35: A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) Vs Idursulfase in Pediatric and Young Adult Participants with Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

Recruiting
2/3
54
Europe, Canada, US, RoW
tividenofusp alfa, idursulfase
Denali Therapeutics Inc.
Mucopolysaccharidosis II
12/25
12/25
NCT06075537: An Extension Study of the Long-Term Safety, Tolerability, and Efficacy of Tividenofusp Alfa (DNL310) in Participants With Mucopolysaccharidosis Type II (MPS II) From Study DNLI-E-0002 or Study DNLI-E-0007

Enrolling by invitation
2/3
99
Europe, Canada, US, RoW
tividenofusp alfa
Denali Therapeutics Inc.
Mucopolysaccharidosis II
06/27
06/27
STAAR, NCT04046224 / 2019-000667-24: Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease

Active, not recruiting
1/2
34
Europe, Canada, US, RoW
ST-920
Sangamo Therapeutics
Fabry Disease
04/25
09/25
Tai, Andrew
SWIFT-2, NCT04718103 / 2020-003611-10: A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Jul 2024 - Dec 2024 : H2'24 - Acceptance of regulatory submission in US (based on SWIFT-1 trial) for asthma
Completed
3
397
Europe, Canada, Japan, US, RoW
GSK3511294, Depemokimab, Placebo
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
04/24
04/24
NCT05757102: A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma

Recruiting
3
292
US, RoW
FF/UMEC/VI, ELLIPTA, FF/VI
GlaxoSmithKline
Asthma
01/27
01/27
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP
Active, not recruiting
3
1667
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
10/25
10/25
Jaensch, Louise
COMPASS, NCT05371613 / 2021-005200-35: A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) Vs Idursulfase in Pediatric and Young Adult Participants with Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

Recruiting
2/3
54
Europe, Canada, US, RoW
tividenofusp alfa, idursulfase
Denali Therapeutics Inc.
Mucopolysaccharidosis II
12/25
12/25
Martin, Donna
NCT05116241: Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children

Completed
2
367
Europe, RoW
BPZE1 pertussis vaccine and placebo, BPZE1 pertussis vaccine and Boostrix, Placebo and Boostrix
ILiAD Biotechnologies
Bordetella Pertussis, Whooping Cough
05/24
05/24
Quinn
MajesTEC-4, NCT05243797 / 2021-002531-27: Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Recruiting
3
1594
Europe, Canada, US, RoW
Teclistamab, JNJ-64007957, Lenalidomide
Stichting European Myeloma Network, Janssen Pharmaceutica
Multiple Myeloma
04/28
04/32
NCT04530123: Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

Recruiting
2
90
Canada, US, RoW
Placebo, TAK-101, Gluten
Takeda
Celiac Disease
10/25
10/25
NCT05621317: A Safety and Efficacy Study of PVX108 in Children and Adolescents with Peanut Allergy

Active, not recruiting
2
90
US, RoW
PVX-108, Placebo
Aravax Pty Ltd
Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Immune System Diseases
11/25
06/27
Balouch, Fariha
NCT06121375: Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy

Recruiting
2/3
144
RoW
OCA, Matching Placebo
Intercept Pharmaceuticals
Biliary Atresia
12/27
12/27
Monteagudo, Eines
NCT02716246 / 2015-003904-21: Phase I/II/III Gene Transfer Clinical Trial of ScAAV9.U1a.hSGSH

Recruiting
2/3
36
Europe, US, RoW
UX111, scAAV9.U1a.hSGSH, ABO-102, rebisufligene etisparvovec, Prophylactic Immunomodulatory (IM) Therapy, Optimized Prophylactic IM Therapy, Adjuvant IM Therapy
Ultragenyx Pharmaceutical Inc, Abeona Therapeutics, Inc
MPS IIIA, Sanfilippo Syndrome, Sanfilippo a, Mucopolysaccharidosis III
07/27
07/27

Download Options